Criteria derived from serum markers can precisely evaluate axillary status in breast cancer patients
详细信息 查看全文
- 作者：Hangyu Wan ; MDa ; 1 ; Zhenggui Du ; MDa ; b ; c ; 1 ; Quanyi Long ; MDa ; b ; Qing Lü ; MDa ; b ; Hongjiang Li ; MDa ; b ; lihongjiang@sohu.com
- 关键词：Breast cancer ; Axillary lymph node metastases ; Sentinel lymph node biopsy ; Chemokine ligand ; Hepatocyte growth factor ; Matrix metalloproteinase
- 刊名：Journal of Surgical Research
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：208
- 期：Complete
- 页码：211-218
- 全文大小：795 K
- 卷排序：208
文摘
A noninvasive method to confirm the presence of lymph node metastases (LNM) in breast cancer patients is lacking. This study aimed to identify markers from peripheral blood that have diagnostic value in evaluating axillary LNM.MethodsWe tested 26 factors in serum from 57 patients with resectable breast cancer by the Luminex assay. Differences between node-negative and node-positive patients were assessed. The diagnostic value of the factors was determined by further analyses and a validation test.ResultsMatrix metalloproteinase-1, hepatocyte growth factor, and chemokine ligand 5 were independent risk factors for LNM. However, receiver operating characteristic analysis showed that these factors alone were not ideal predictors. The LNM score (LNMS), derived from combining these markers, correlated significantly with numbers of positive lymph nodes. Patients with LNMS of 0 had few LNM, axillary lymph node dissection (ALND) could be avoided, and sentinel lymph node biopsy (SLNB) was unnecessary. Very high accuracy was achieved for patients with LNMS of 1 with SLNB using only methylene blue, patients with LNMS of 3 required ALND, and patients with LNMS of 2 needed SLNB using both a radioactive isotope and methylene blue, and ALND.ConclusionsThe LNMS derived from matrix metalloproteinase-1, hepatocyte growth factor, and chemokine ligand 5 serum levels identified the axillary lymph node status with high accuracy. Patients with higher LNMS had a greater probability of LNM.